DALK with hydrops is safe and effective

Article

Deep anterior lamellar keratoplasty (DALK) is a safe and effective procedure in keratoconic eyes with previous hydrops.

Deep anterior lamellar keratoplasty (DALK) is a safe and effective procedure in keratoconic eyes with previous hydrops.

The retrospective, non-comparative study, led by Sheraz M Daya, Centre for Sight, East Grinstead, UK, involved 10 eyes of 10 patients. Each patient has previously receieved hydrops and underwent DALK.

DALK was completed using the Melles's technique of optical recognition with pre-Descemet's membrane dissection. The outcome measures included preoperative and postoperative uncorrected distance visual acuity and best spectacle corrected distance visual acuity (BSCVA), postoperative spherical equivalent (SEQ), keratometry and adverse events.

Preoperative BSCVA was 6/24 or worse in all eyes and at the last follow-up it was 6/12 or better in all eyes. Six eyes experienced intraoperative microperforation but penetrating keratoplasty conversion was not required.

The mean SEQ was −2.4±4.2 D, keratometric astigmatism was 3.8±1.6 D and refractive astigmatism was 3.4±2.2 D, whereas the mean postoperative keratometry was 43.7±2.6 and central pachymetry 572.6±65.0 µm.

The study can be found in the British Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.